We are live on ! Find out more
ATYR

aTyr Pharma

52 hedge funds and large institutions have $23.1M invested in aTyr Pharma in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

21% more funds holding

Funds holding: 4352 (+9)

3.24% more ownership

Funds ownership: 0%3.24% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

32% less capital invested

Capital invested by funds: $33.9M → $23.1M (-$10.8M)

Holders
52
Holders Change
+9
Holders Change %
+20.93%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
14
Increased
11
Reduced
15
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$59K +$23.3K +568 +41%
Russell Investments Group
27
Russell Investments Group
United Kingdom
$59K +$75.6K +1,843 New
QI
28
Quotient Investors
New York
$48K
Northern Trust
29
Northern Trust
Illinois
$44K +$1.15K +28 +2%
VKH
30
Virtu KCG Holdings
New York
$43K +$58.5K +1,425 New
BlackRock
31
BlackRock
New York
$42K -$8.74K -213 -13%
AIM
32
Alambic Investment Management
California
$40K +$53.9K +1,314 New
BG
33
BlackRock Group
United Kingdom
$36K
WS
34
Wedbush Securities
California
$30K +$41K +1,000 New
ARTA
35
A.R.T. Advisors
New York
$29K +$40.1K +977 New
Creative Planning
36
Creative Planning
Kansas
$28K +$14.7K +358 +63%
AIM
37
Acrospire Investment Management
Illinois
$27K +$37.2K +906 New
Morgan Stanley
38
Morgan Stanley
New York
$24K +$25.2K +615 +322%
PP
39
Paloma Partners
Connecticut
$22K +$30.1K +733 New
Citigroup
40
Citigroup
New York
$16K -$12.7K -309 -37%
Parallax Volatility Advisers
41
Parallax Volatility Advisers
California
$14K +$18.5K +450 New
Barclays
42
Barclays
United Kingdom
$12K +$16.7K +407 +20,350%
Acadian Asset Management
43
Acadian Asset Management
Massachusetts
$11K
BJ
44
BlackRock Japan
Japan
$7K -$574 -14 -6%
BIM
45
BlackRock Investment Management
Delaware
$6K
DADC
46
D.A. Davidson & Co
Montana
$4K +$5.87K +143 New
UBS Group
47
UBS Group
Switzerland
$3K -$55.3K -1,347 -92%
Federated Hermes
48
Federated Hermes
Pennsylvania
$2K -$1.64M -39,897 -100%
TRCT
49
Tower Research Capital (TRC)
New York
$2K -$1.15K -28 -26%
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K

ATYR Hedge Fund Activity: Q4 2016 in Review

52 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2016, worth a combined $23.1M — down 32% from $33.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ATYR positions and 4 closed out — a net gain of 10 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $2.86M. The largest seller was Federated Hermes, cutting an estimated $1.64M.

  • 52 institutional investors held aTyr Pharma (ATYR) as of Q4 2016, up from 43 in Q3 2016.
  • Funds reported $23.1M of aTyr Pharma stock for Q4 2016, down 32% quarter-over-quarter.
  • 14 funds opened new aTyr Pharma positions in Q4 2016 and 4 closed out, a net change of +10 holders.
  • The largest aTyr Pharma buyer in Q4 2016 was EcoR1 Capital, an estimated $2.86M added.
  • The largest aTyr Pharma seller in Q4 2016 was Federated Hermes, an estimated $1.64M sold.

Based on aggregated 13F filings for Q4 2016.